Market Overview

Genprex Enters Agreement with the University of Texas MD Anderson Cancer Center to Study Oncoprex in Combination with Immunotherapies


New study will evaluate synergistic effect of Oncoprex gene therapy on
checkpoint inhibition

Study may identify biomarkers that can predict the response to
therapy across different cancers

(NASDAQ:GNPX), a clinical stage gene therapy company developing
a new approach to treating cancer based upon a novel proprietary
technology platform, has entered a Sponsored Research Agreement
("Agreement") with The University of Texas MD Anderson Cancer Center
under which Genprex will sponsor a pre-clinical study, entitled "A Novel
Therapeutic Approach for the Treatment of Cancer Using a Combination of
the Multifactorial Tumor Suppressor Gene TUSC2 and Immunotherapy," to be
conducted under the direction of Jack A. Roth, MD, FACS. TUSC2 is the
active agent in Genprex's investigational drug candidate Oncoprex™.

The study, which is built upon strong data from pre-clinical research
conducted at MD Anderson, is intended to develop a novel therapeutic
approach for the treatment of cancer using a combination of the
multifactorial tumor suppressor gene TUSC2 and immunotherapy, including
the immune checkpoint inhibitors anti-PD1 and/or anti CTLA-4. The study
will include the identification of biomarkers to predict the response to
TUSC2-immunotherapy combinations.

Under the Agreement, MD Anderson will provide all necessary personnel,
equipment, supplies, facilities and resources to perform the study; and
Genprex will pay MD Anderson an amount equal to its expenditures and
reasonable overhead in conducting the study in an amount of $2.0 million.

"This research program will evaluate the ability of TUSC2 gene therapy
to synergistically enhance the effect and clinical utility of anti-PD1
and/or anti-CTLA-4 therapies," said Rodney Varner, Chairman and Chief
Executive Officer of Genprex. "Identifying biomarkers that can predict
response rates for Oncoprex-immunotherapy combinations may allow us to
explore the utility of this treatment regimen in a broader array of

Varner added, "While immunotherapies represent an important advance in
treating cancer, even in highly immunogenic tumors, the majority of
patients do not respond to checkpoint inhibition. Combination therapies
targeting multiple anti-cancer pathways represent a promising approach
to achieving greater response rates, and may also allow the expanded use
of immunotherapies in a larger population of cancer patients who are not
currently candidates for these treatments."

Researchers at MD Anderson reported
from preclinical research at the 2017 meeting of the American
Association for Cancer Research demonstrating that TUSC2 alone or in
combination with checkpoint blockade (anti-PD-1 and/or anti-CTLA4)
significantly prolonged mouse survival in a non-small cell lung cancer
metastasis model compared to checkpoint blockade alone. The greatest
increase in survival was seen with TUSC2 combined with checkpoint
blockade. The treatment response was associated with high infiltration
of natural killer (NK) cells and CD8 T cells, and low infiltration of
myeloid-derived suppressor cells (MDSC) in the tumor microenvironment.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new
approach to treating cancer, based upon a novel proprietary technology
platform, including Genprex's initial product candidate, Oncoprex™
immunogene therapy for non-small cell lung cancer (NSCLC). Genprex's
platform technologies are designed to administer cancer fighting genes
by encapsulating them into nanoscale hollow spheres called nanovesicles,
which are then administered intravenously and taken up by tumor cells
where they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts cell
signaling pathways that cause replication and proliferation of cancer
cells, re-establishes pathways for apoptosis, or programmed cell death,
in cancer cells, and modulates the immune response against cancer cells.
Oncoprex has also been shown to block mechanisms that create drug

For more information, please visit or

Forward-Looking Statements

Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effect of TUSC2 on cancer, the services we
expect to receive from MD Anderson and the effect of those services on
the development of Oncoprex. Risks that contribute to the uncertain
nature of the forward-looking statements include the presence and level
of TUSC2's effect on cancer, MD Anderson's ability to provide services
to us and our ability to utilize MD Anderson's services, the ability of
MD Anderson's services to influence the development of Oncoprex, as well
as the timing and success of our clinical trials and planned clinical
trials of TUSC2 and Oncoprex and our other potential product candidates
and the timing and success of obtaining FDA approval of Oncoprex and our
other potential product candidates. These and other risks and
uncertainties are described more fully under the caption "Risk Factors"
and elsewhere in our filings and reports with the United States
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which they
were made. We undertake no obligation to update such statements to
reflect events that occur or circumstances that exist after the date on
which they were made.

View Comments and Join the Discussion!